汪有彪 徐焱江 江兴华 冯绍谦

摘 要 目的：探讨参芪扶正注射液联合亮丙瑞林治疗晚期前列腺癌的临床效果。方法：选取74例晚期前列腺癌患者，根据用药方式不同分为对照组和观察组各37例。对照组采用亮丙瑞林治疗，观察组采用参芪扶正注射液联合亮丙瑞林治疗，观察两组用药后的疗效及不良反应发生率。结果：观察组的疗效高于对照组；前列腺特异性抗原和血清睾酮水平低于对照组；不良反应发生率低于对照组（P<0.05）。结论：参芪扶正注射液联合亮丙瑞林治疗晚期前列腺癌的疗效更好，不良反应发生率更低。

关键词 晚期前列腺癌 参芪扶正注射液 亮丙瑞林

中图分类号：R286； R737.25 文献标志码：B 文章编号：1006-1533（2021）07-0041-03

Effect of Shenqi Fuzheng injection combined with leuprolide in the treatment of advanced prostate cancer

WANG Youbiao， XU Yanjiang， JIANG Xinghua， FENG Shaoqian

（Department of Urology， the Second Peoples Hospital of Jingdezhen City， Jiangxi Jingdezhen 333000， China）

ABSTRACT Objective： To explore the clinical effect of Shenqi Fuzheng injection combined with leuprorelin in the treatment of advanced prostate cancer. Methods： A total of 74 patients with advanced prostate cancer were divided into a control group and an observation group with 37 cases each based on their different medication methods. The control group was treated with leuprolide alone while the observation group with Shenqi Fuzheng injection combined with leuprolide. The efficacy and the incidence of adverse reactions were compared between the two groups after treatment. Results： The overall treatment efficiency was significantly higher and the levels of prostate-specific antigen and serum testosterone and the incidence of adverse reactions were lower in the observation group than the control group （P<0.05）. Conclusion： The efficacy of Shenqi Fuzheng injection combined with leuprolide for the treatment of advanced prostate cancer is better and its incidence of adverse reactions is significantly lower.

KEy WORDS advanced prostate cancer； Shenqi Fuzheng injection； leuprorelin

前列腺癌是男性特有的生殖系统恶性肿瘤，中老年人中较为常见，且随着年龄的增长发病率会逐渐升高。在临床上可通过药物进行治疗，参芪扶正注射液及亮丙瑞林是治疗该病症的两种主要药物，前者能增强巨噬细胞功能，改善患者病症情况，患者在用药后可改善自身精力低下、少气懒言以及眩晕等症状，药效较好[1]；后者是合成促性腺激素释放激素十肽同类物，具有促进激素分泌的作用[2]。

1 资料与方法

1.1 一般資料

选取景德镇市第二人民医院2018年1月—2020年1月收治的74例晚期前列腺癌患者作为研究对象，根据用药方式的不同分为对照组和观察组各37例。其中对照组年龄57～72岁，平均年龄（66.84±4.17）岁；病程1～3年，平均病程（2.07±0.38）年。观察组年龄55～69岁，平均年龄（63.62±3.78）岁；病程1～3年，平均病程（2.13±0.42）年。两组患者一般资料比较差异无统计学意义（P>0.05），具可比性。

纳入标准：①经病理诊断确诊为晚期前列腺癌；②……